Silence Therapeutics (NASDAQ:SLN) Given “Outperform” Rating at William Blair

William Blair reiterated their outperform rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Tuesday,RTT News reports.

Other equities analysts have also issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, November 15th. Jefferies Financial Group began coverage on Silence Therapeutics in a report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $57.20.

Silence Therapeutics Stock Down 8.7 %

Shares of Silence Therapeutics stock opened at $7.01 on Tuesday. Silence Therapeutics has a twelve month low of $5.81 and a twelve month high of $27.72. The business has a 50-day moving average price of $16.90 and a 200 day moving average price of $18.68. The firm has a market cap of $209.81 million, a PE ratio of -4.46 and a beta of 1.30.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Values First Advisors Inc. acquired a new position in shares of Silence Therapeutics during the 3rd quarter worth approximately $56,000. Quarry LP acquired a new position in shares of Silence Therapeutics during the 2nd quarter worth approximately $114,000. SG Americas Securities LLC raised its position in shares of Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after buying an additional 667 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Silence Therapeutics during the 3rd quarter valued at approximately $207,000. Finally, Custom Index Systems LLC purchased a new stake in shares of Silence Therapeutics during the 2nd quarter valued at approximately $282,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.